Compare PODD & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | MEDP |
|---|---|---|
| Founded | 2000 | 1992 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.7B |
| IPO Year | 2007 | 2016 |
| Metric | PODD | MEDP |
|---|---|---|
| Price | $170.91 | $419.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 12 |
| Target Price | $341.48 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 902.9K | 451.2K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 3.48 | ★ 4.28 |
| Revenue | ★ $2,708,100,000.00 | N/A |
| Revenue This Year | $24.55 | $13.19 |
| Revenue Next Year | $19.18 | $7.75 |
| P/E Ratio | ★ $46.25 | $96.40 |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $158.35 | $284.10 |
| 52 Week High | $354.88 | $628.92 |
| Indicator | PODD | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 37.09 |
| Support Level | N/A | $382.68 |
| Resistance Level | $205.95 | $485.13 |
| Average True Range (ATR) | 7.04 | 17.73 |
| MACD | -1.91 | -11.32 |
| Stochastic Oscillator | 26.32 | 29.20 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.